Cargando…

Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation: Therapeutic Implications

KRAS, one of the RAS protein family members, plays an important role in autophagy and apoptosis, through the regulation of several downstream effectors. In cancer cells, KRAS mutations confer the constitutive activation of this oncogene, stimulating cell proliferation, inducing autophagy, suppressin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Anabela, Pereira, Flávia, Reis, Celso, Oliveira, Maria José, Sousa, Maria João, Preto, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319879/ https://www.ncbi.nlm.nih.gov/pubmed/35883626 http://dx.doi.org/10.3390/cells11142183

Ejemplares similares

KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
por: Pereira, Flávia, et al.
Publicado: (2022)

Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
por: Alves, Sara, et al.
Publicado: (2015)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate
por: Kordiak, Jacek, et al.
Publicado: (2018)

Modulation of Fibroblast Phenotype by Colorectal Cancer Cell-Secreted Factors Is Mostly Independent of Oncogenic KRAS
por: Dias Carvalho, Patrícia, et al.
Publicado: (2022)

KRAS insertion mutations are oncogenic and exhibit distinct functional properties
por: White, Yasmine, et al.
Publicado: (2016)

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer
por: Sánchez-Muñoz, Alfonso, et al.
Publicado: (2010)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021)

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations
por: Choi, Jaewon, et al.
Publicado: (2021)

Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations
por: Ha, Dat P., et al.
Publicado: (2022)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
por: Conti, Annalisa, et al.
Publicado: (2015)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

Immune modulatory effects of oncogenic KRAS in cancer
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

Targeting the undruggable oncogenic KRAS: the dawn of hope
por: Asimgil, Hande, et al.
Publicado: (2022)

Conquering oncogenic KRAS and its bypass mechanisms
por: Hou, Pingping, et al.
Publicado: (2022)

Computational Analysis of KRAS Mutations: Implications for Different Effects on the KRAS p.G12D and p.G13D Mutations
por: Chen, Chih-Chieh, et al.
Publicado: (2013)

Prognostic Value of Autophagy, Microsatellite Instability, and KRAS Mutations in Colorectal Cancer
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma
por: Unni, Arun M, et al.
Publicado: (2015)

KRAS mutation in lung metastases from colorectal cancer: prognostic implications
por: Ghidini, Michele, et al.
Publicado: (2015)

Oncogenic KRAS G12D mutation promotes dimerization through a second, phosphatidylserine–dependent interface: a model for KRAS oligomerization
por: Lee, Ki-Young, et al.
Publicado: (2021)

Cathepsin D protects colorectal cancer cells from acetate-induced apoptosis through autophagy-independent degradation of damaged mitochondria
por: Oliveira, C S F, et al.
Publicado: (2015)

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas
por: Salmón, Marina, et al.
Publicado: (2023)

Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
por: Sabnis, Amit J, et al.
Publicado: (2009)

Metastatic Pancreatic Cancer Is Dependent on Oncogenic Kras in Mice
por: Collins, Meredith A., et al.
Publicado: (2012)

Oncogenic KRAS promotes malignant brain tumors in zebrafish
por: Ju, Bensheng, et al.
Publicado: (2015)

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu, Xinquan, et al.
Publicado: (2019)

Pancreatic Tumorigenesis: Oncogenic KRAS and the Vulnerability of the Pancreas to Obesity
por: Luo, Yongde, et al.
Publicado: (2021)

Oncogenic KRAS alters splicing factor phosphorylation and alternative splicing in lung cancer
por: Lo, April, et al.
Publicado: (2022)

Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
por: Learte-Aymamí, Soraya, et al.
Publicado: (2022)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
por: Aran, Veronica, et al.
Publicado: (2021)

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
por: Tape, Christopher J., et al.
Publicado: (2016)

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms
por: Lee, Yi-Ju, et al.
Publicado: (2016)

Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation
por: Charitou, Theodosia, et al.
Publicado: (2019)

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis
por: Le Roux, Özgün, et al.
Publicado: (2022)

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer
por: Shin, Dong Hoon, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g4akcrfmdkeabkqe7t5bnhrpvf